Inhibrx Biosciences/$INBX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Inhibrx Biosciences

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Ticker

$INBX
Sector
Health
Primary listing
NASDAQ

Employees

159
Headquarters
La Jolla, United States
Website
inhibrx.com

INBX Metrics

BasicAdvanced
$516M
-
-$10.58
-
-

What the Analysts think about INBX

Analyst ratings (Buy, Hold, Sell) for Inhibrx Biosciences stock.

Bulls say / Bears say

In January 2025, Inhibrx secured a $100 million initial draw (up to $150 million available) through a five-year term loan from Oxford Finance, providing non-dilutive funding to advance its INBRX-109 and INBRX-106 programs through critical 2025 data milestones (PRNewswire).
Preliminary Phase 1 results for ozekibart (INBRX-109) in advanced colorectal adenocarcinoma reported one complete response, three partial responses, and a median progression-free survival of 7.85 months, showing encouraging early efficacy and sustained disease control (PRNewswire).
Inhibrx fully enrolled its registration-enabling Phase 2 trial in unresectable or metastatic conventional chondrosarcoma in July 2025, placing the company on track for a potentially pivotal data readout by late October 2025 (PRNewswire).
Net loss of $28.7 million in Q2 2025 highlights a high cash burn rate, with $186.6 million in cash reserves covering only about six quarters at the current pace, raising the risk of a funding shortfall if additional capital isn’t secured (GuruFocus).
Both leading candidates—INBRX-109 and INBRX-106—are still in Phase 1/2 trials with no regulatory approvals or late-stage data, exposing the company to substantial clinical and regulatory risks (SEC).
Under the Oxford Finance term loan, Inhibrx issued warrants to purchase 140,741 shares (2% of the initial $100 million draw), introducing potential dilution that could pressure shareholder value (PRNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

INBX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

INBX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INBX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs